Similarly, treatment with the ATP-competitive IGF-1R/InsR dual inhibitor OSI-906, which blocks downstream activation of PI3K in MCF-7 cells, slowed tumor growth and induced regression when combined with fulvestrant (Fox et al., 2011). This evidence concerns the gene PIK3CA and neoplasm.